Patent details

Basic Information

Publication number:

LUC50037

Type:

SPC

SPC Type:

Medical

Basic Patent Number:

EP231716309

Legal Status:

Pending & Published

Application number:

LUC50037

First applicant's nationality:

Procedural language:

French

Marketing Authorization

Marketing Authorization Number:

EU/1/23/1770

Marketing Authorization Type:

Marketing Authorization Date:

08/12/2023

Marketing Authorization Status:

Accepted

Marketing Authorization Country:

Luxembourg (LU)

Dates

Filing date:

16/02/2026

First Marketing Authorization date:

08/12/2023

Grant date:

Activation date:

Publication date:

17/02/2026

Lapsed date:

Expiration date:

Renunciation date:

Revocation date:

Annulment date:

Basic SPC Expiration:

08/12/2038

SPC Extension Expiration:

08/12/2038

Rejection date:

Withdrawal date:

Owner

From:

16/02/2026

 

 

Name:

Pfizer Inc.

Address:

66 Hudson Boulevard East, New York, NY 10001-2192, United States (US)

Agent

Name:

OFFICE FREYLINGER S.A.

From:

16/02/2026

Address:

Boîte Postale 48, L-8001, STRASSEN, Luxembourg (LU)

To:

Publication

Bulletin

Bulletin Heading:

SPC1

Bulletin edition number:

2026/04

Publication date:

03/03/2026

Description:

Section C : Published requests for Supplementary Protection Certificates – I1 publication

Filing date	Document type	Number of pages
16/02/2026	Application Form	5
16/02/2026	Outgoing Correspondence	2
16/02/2026	General Document	42
16/02/2026	General Document	1
16/02/2026	General Document	1
16/02/2026	General Document	4
16/02/2026	General Document	8
17/02/2026	Outgoing Correspondence	1
17/02/2026	Publication	1